Sepsis Gene-Edited Cell Lines for Drug Discovery Research

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. According to the World Health Organization (WHO), sepsis affects approximately 49 million people annually worldwide, resulting in 11 million deaths (one in five of all global deaths). The incidence is highest in low- and middle-income countries, but sepsis remains a leading cause of death in high-income settings as well. Key risk factors include age (very young and elderly), immunosuppression, chronic diseases (diabetes, cancer, kidney disease), and invasive medical procedures. The 5-year survival rate after sepsis is approximately 50%, with survivors often suffering long-term cognitive, physical, and psychological impairments (NCI, WHO).

Sepsis is a complex, heterogeneous syndrome involving multiple cell types, signaling pathways, and organ systems. Its study is ideal for mechanistic research due to the availability of public datasets (e.g., GEO, TCGA for sepsis-related gene expression), well-characterized cell lines (e.g., THP-1, RAW 264.7), and open questions regarding the transition from hyperinflammation to immunosuppression. Key research areas include identifying novel therapeutic targets, understanding immune cell dysfunction, and developing biomarkers for early diagnosis and prognosis. Gene-edited cell models are essential for dissecting the role of specific genes in these processes.

Sepsis pathogenesis involves a dysregulated immune response to infection. Key pathways include:

• • Pathogen Recognition: Pathogen-associated molecular patterns (PAMPs) bind to pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs).

1. PAMPs (e.g., LPS, flagellin) bind to PRRs on immune cells.

2. This triggers intracellular signaling cascades (e.g., MyD88, TRIF).

3. Activation of transcription factors (NF-κB, IRF3) leads to pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β).

• • Cytokine Storm: Excessive release of cytokines causes systemic inflammation, endothelial damage, and microvascular thrombosis.
• • Immunosuppression: Prolonged sepsis leads to T-cell exhaustion, monocyte deactivation, and increased anti-inflammatory cytokines (IL-10, TGF-β).
• • Metabolic Reprogramming: Immune cells shift from oxidative phosphorylation to glycolysis (Warburg effect), contributing to dysfunction.

While sepsis is not a cancer, genetic polymorphisms and somatic mutations in immune-related genes influence susceptibility and outcomes. Data from GWAS and sequencing studies (NCBI Gene, ClinVar) highlight key variants:

Sepsis involves multiple interconnected signaling networks:

• • TLR/NF-κB Pathway: Central to pro-inflammatory cytokine production. Key nodes: TLR4, MyD88, IRAK1, TRAF6, IKK complex, NF-κB.
• • JAK/STAT Pathway: Mediates cytokine signaling (e.g., IL-6, IFN-γ). Key nodes: JAK1, JAK2, STAT3, STAT1.
• • PI3K/AKT/mTOR Pathway: Regulates cell survival, metabolism, and inflammation. Key nodes: PI3K, AKT, mTOR, S6K.
• • MAPK Pathway: Involved in cytokine production and apoptosis. Key nodes: p38, JNK, ERK.
• • Inflammasome Pathway: NLRP3 inflammasome activation leads to IL-1β and IL-18 release. Key nodes: NLRP3, ASC, Caspase-1.

Commonly used cell lines for sepsis research:

Organoids (e.g., lung, gut, kidney) derived from patient samples or iPSCs offer a more physiologically relevant 3D model for studying sepsis-induced organ damage and testing therapeutics.

Animal models are critical for studying sepsis in a whole-organism context:

• • Cecal Ligation and Puncture (CLP): Most clinically relevant model of polymicrobial sepsis.
• • LPS Injection: Induces endotoxemia, useful for studying TLR4 signaling.
• • Cecal Slurry Injection: Intraperitoneal injection of cecal contents to induce peritonitis.
• • Genetically Engineered Mouse Models (GEMM): Knockout or transgenic mice for specific genes (e.g., TLR4-/-, MyD88-/-).
• • Patient-Derived Xenograft (PDX): Not common for sepsis, but used for studying sepsis in cancer patients.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, allowing researchers to study the function of specific genes in sepsis pathways. Examples include:

• • TLR4 Knockout: THP-1 or HEK293 cells with TLR4 deletion to study LPS signaling.
• • MyD88 Knockout: Cells lacking MyD88 to investigate TLR/IL-1R signaling.
• • NLRP3 Knockout: Macrophage lines with NLRP3 deletion to study inflammasome activation.
• • NF-κB Reporter Lines: Cells with a luciferase or GFP reporter under NF-κB control for high-throughput screening.
• • Cytokine Knock-In: Cells expressing mutant forms of TNF-α or IL-6 to study gain-of-function effects.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent, validated tools for target validation, drug screening, and mechanistic studies. These models are available from commercial sources and can be customized for specific research needs.

Gene-edited cell lines are essential for functional genomics studies in sepsis:

• • Knockout Validation: Deleting a gene (e.g., TLR4, MyD88) in THP-1 cells confirms its role in cytokine production after LPS stimulation.
• • Knock-In Studies: Introducing patient-specific variants (e.g., TLR4 D299G) into isogenic lines to assess functional impact on immune signaling.
• • CRISPR Screens: Genome-wide knockout libraries in macrophages or endothelial cells identify genes essential for sepsis pathogenesis (e.g., regulators of cytokine storm).

Isogenic cell pairs (wild-type vs. knockout) are powerful tools for drug screening:

• • Target Identification: Compare drug responses in TLR4-/- vs. wild-type cells to identify compounds that act through TLR4.
• • Resistance Modeling: Generate cells with mutations in drug targets (e.g., JAK inhibitors) to study resistance mechanisms.
• • High-Throughput Screening: Use NF-κB reporter lines to screen libraries for inhibitors of the inflammatory response.

CRISPR-engineered cells facilitate biomarker discovery:

• • Synthetic Lethality Screens: Identify genes that, when knocked out, sensitize cells to sepsis-related stressors (e.g., hypoxia, oxidative stress).
• • Secretome Analysis: Compare cytokine profiles from wild-type vs. knockout cells to identify novel biomarkers.
• • Reporter Lines: Monitor pathway activation (e.g., NF-κB, STAT3) in real-time to identify early biomarkers of sepsis.